Gilead Surges 2.02% on $790M Volume Spike, Ranks 125th in Trading Activity as Key Trial Update Drives Momentum

. 5, , . The move followed updates on a pivotal Phase 3 trial of its experimental oncology drug (SG) for extensive-stage small cell lung cancer (ES-SCLC).

The study, . , , compares SG to standard therapies like and in patients with ES-SCLC, a condition with limited treatment options. Participants are randomized into two groups, with SG administered intravenously. The trial focuses on and , with primary results expected soon after the initial completion date. . , , signaling ongoing progress.

Investors are closely watching the trial’s outcome, as positive results could strengthen Gilead’s position in the oncology market. Success in demonstrating SG’s superiority over existing treatments may drive demand for the drug and influence broader treatment protocols. The study’s open-label design and direct comparison to established therapies add to its significance in evaluating clinical efficacy.

I can definitely help design and back-test this idea. However, with the current tool set we need to know the exact list of stocks (or a proxy index) that will represent “the top-500-by-volume” each day. At the moment the tools work on one ticker (or an index ticker) at a time.

Two practical ways forward: 1. Use a proxy index/ETF (e.g., SPY, , or a custom equal-weight index ticker, if you have one) and treat buying that instrument as standing in for the basket each day. 2. Provide (or upload) a daily list of the 500 tickers you’d like included. I can then generate the daily buy/sell signals from that list.

Which approach would you like to pursue?